Experimental Alzheimer’s drug could reduce alcohol withdrawal damage, researchers say

[aggregator] downloaded image for imported item #83327

This post was originally published on this site.

An investigational dementia drug may also ease alcohol withdrawal by calming the brain inflammation linked toaddictionand relapse.

That’s according to researchers at the University of Kentucky, who studied an experimental medication called MW150 that targets a brain inflammation pathway known as p38α MAPK.

The drug, which has not yet been approved, is designed to treatmild to moderateAlzheimer’s disease.

ALCOHOL DEATHS HAVE MORE THAN DOUBLED IN RECENT YEARS, ESPECIALLY AMONG WOMEN

Scientists believe neuroinflammation may contribute to relapse risk and long-term neurological damage in people withalcohol use disorder.

In laboratory and animal-model experiments, MW150 was found to reduce certain inflammatory markers during alcohol withdrawal.

Young woman sitting in kitchen holding her head and a glass of water

An investigational dementia drug may also ease alcohol withdrawal by calming the brain inflammation linked to addiction and relapse.(iStock)

The work, which was published in the journal Alcohol, came from the University of Kentucky’s Sanders-Brown Center on Aging, led by neuroinflammation researcher Linda Van Eldik.

ALCOHOL POSES THESE 8 RISKS TO OLDER ADULTS, EXPERTS WARN

Caleb Bailey, Ph.D., co-author of the study and a researcher in Van Eldik’s lab, said the study provides “biological plausibility” that MW150 could mitigate neuroinflammation arising from alcohol withdrawal.

Alcohol use disorder is difficult to treat because ofhigh relapse rates, especially during withdrawal, according to Bailey.

Man refusing to drink alcohol at a pub

Alcohol use disorder is difficult to treat because of high relapse rates, especially during withdrawal, according to the researchers.(iStock)

“If follow-up experiments reveal similar anti-inflammatory effects of MW150 in animal models of alcohol use disorder, it would provide a strong rationale for development of MW150 as a treatment for those struggling with chronic alcohol relapse due to alcohol withdrawal,�

‘I”M A NEUROSURGEON — HERE’S WHAT ALCOHOL DOES TO THE BODY’

Along with a related drug called Neflamapimod, MW150 is already being investigated in clinical trials as apotential therapy for dementiaand other neurodegenerative conditions, the researchers noted.

“That gives this work added significance,” Bailey said.“Because these compounds are already further along in development for other neurological diseases, it raises the possibility that they could someday be repurposed more efficiently for alcohol-related conditions iffuture studiescontinue to show promise.”

There were some important caveats to the research, including that it was conducted in cell culture and animal models.

“Because they are ‘dish’-based models, they provide limited information regarding what happens in the full organism – or even the full brain for that matter,” Bailey said.

Senior woman holding a white pill near her mouth ready to take it with a glass of water

MW150, along with a related drug called Neflamapimod, is already being investigated in clinical trials as a potential therapy for dementia and other neurodegenerative conditions.(iStock)

“A series of follow-up studies in living animals is required to more fully understand how future MW150 treatment in alcohol use and withdrawal affectssystemic healthand/or alcohol consumption.”

Dr.Amy Swift, deputy chief medical officer at Silver Hill Hospital in Connecticut, was not involved in the study but shared her reactions to the findings.

“Although detoxification using tapering doses of medication has long been considered the evidence-based first step in treating alcohol use disorder, its impact on the long-term trajectory of a person’s drinking behavior has been limited,�

“Minimizing alcohol consumption … is the best strategy for staying healthy.”

“Put simply, detoxification does not treat alcohol use disorder itself;rather, it prevents the potentially fatal complications of alcohol withdrawal.”

onelink.me/xLDS?pid=AppArticleLink&af_web_dp=https%3A%2F%2Fwww.

Adding supportive medications — especially those intended to improve overallbrain health— could address an important gap in early treatment of detoxification, according to Swift.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top